Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance
Open Access
- 12 September 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-12
Abstract
Resistance to immunotherapy poses a significant challenge in the treatment of colorectal cancer (CRC), and the underlying mechanisms are not fully understood. Recent studies have implicated PFKFB3, a crucial glycolytic enzyme, in shaping the tumor microenvironment in CRC. Our study aimed to systematically study the role of PFKFB3 in CRC. Bioinformatic analysis revealed that PFKFB3 expression is notably elevated in CRC tissues compared to normal counterparts. In vivo experiments confirmed that suppressing PFKFB3 reduces the tumorigenesis of CRC. We identified multiple cancer-associated pathways positively correlated with high expression of PFKFB3, such as epithelial-mesenchymal transition (EMT), hypoxia, KRAS signaling, angiogenesis, PI3K/AKT/mTOR, Hedgehog, and Notch pathways. Additionally, PFKFB3 exhibited significant correlations with various immune-related pathways, including complement, IL-2/STAT5, IL-6/JAK/STAT3, IFN-α/IFN-γ, TGF-β, and TNF-α/NF-κB, as well as several immunosuppressive cell markers found in regulatory T cells (CCR8, TGFB1, STAT5B, FOXP3), M2 macrophages (CD163, VSIG4, MS4A4A), T cell exhaustion markers (CTLA-4, PDCD1, LAG3), and PD-L1. Intriguingly, increased PFKFB3 expression was observed in PD-L1 blockade-resistant patients and was associated with shorter overall survival. In a nutshell, PFKFB3 plays an important role in CRC tumorigenesis and resistance to immunotherapy. Targeting PFKFB3 inhibits tumor formation and enhances the efficacy of immunotherapy. Our findings underscore the functions of PFKFB3 in CRC, shedding light on both cancer-related and immunosuppressive pathways.Keywords
Funding Information
- National Natural Science Foundation of China (81772543)
- Baoding Technology Project (2241ZF046)
- Natural Science Foundation of Hebei Province (H2024104001)
This publication has 48 references indexed in Scilit:
- Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves ChemotherapyCancer Cell, 2016
- Deubiquitination and Stabilization of PD-L1 by CSN5Cancer Cell, 2016
- Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancerBreast Cancer Research and Treatment, 2016
- A nineteen gene‐based risk score classifier predicts prognosis of colorectal cancer patientsMolecular Oncology, 2014
- Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathwayNature Communications, 2014
- Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against CancerMolecular Cancer Therapeutics, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphateTrends in Biochemical Sciences, 2001
- On the Origin of Cancer CellsScience, 1956